Fermion and Simcere Enter into Exclusive Licensing and Collaboration Agreement for China's First SSTR4 Stimulant Targeting Pain By Investing.com

Guangzhou, China, January 17, 2025 /PRNewswire/ — Guangzhou Vermion Technology Co., Ltd and Simcere Pharmaceutical (Tadawul:) Group Limited The Hong Kong Stock Exchange (HKEX: 2096) announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, that targets SSTR4.

FZ002-037 is a highly selective oral small molecule SSTR4 agonist developed by Fermion. Preclinical studies suggest that the drug provides primarily peripheral analgesia without central side effects or addiction risks, making it a promising option for patients requiring long-term pain management. It is the first indigenously developed SSTR4 agonist in China It is the second largest in the world to reach the clinical stage. The drug has completed the first phase of clinical trials in ChinaPhase 2 studies for diabetic peripheral neuropathy are scheduled to begin soon. Potential applications extend to various chronic and acute pain conditions.

“We are delighted to partner with Simcere, a leading pharmaceutical company. As the first indigenously developed SSTR4 agonist and the world's second highly selective SSTR4 agonist to enter the clinical stage, FZ002-037 carries a remarkable title and by leveraging With Simcere's strong development and commercialization capabilities, we are confident of accelerating its progress to provide better treatment options for patients suffering from pain.

Zhou Gaobo, Chief Investment Officer of Simcere, added: “Pain greatly impacts patients’ quality of life and remains a major unmet clinical need. Addressing these ‘clinical pain points’ has always been a core mission of Simcere. We look forward to collaborating with innovative partners such as “Fermion to deliver more effective and safer pain treatments to patients as quickly as possible.”

Under the agreement, Simcere will obtain exclusive rights to develop and commercialize FZ002-037 Greater China (Mainland China, Hong Kong, Macauand Taiwan). Fermion will receive an upfront payment, milestone payments, and tiered royalties based on future sales.

About fermion technology

Fermion is an AI-driven biotechnology company founded in 2019. The company is focused on developing differentiated best-in-class (BIC) and first-in-class (FIC) products in the central nervous system (CNS) and autoimmunity. Fields. Leveraging its Drug Studio AI platform, Fermion prioritizes high target selectivity and tissue targeting to minimize off-target effects, ensure precise distribution in target tissues, and advance the development of innovative drugs with improved safety profiles.

For more information, please visit: www.fulmz.com.

on Simser Pharmaceutical Company

Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company based on innovative R&D, housing the “State Key Laboratory for Neuro-Oncology Drug Development”. Simcere is committed to “providing today's patients with the medicines of tomorrow” across the following core therapeutic areas: oncology, central nervous system, autoimmunity, and anti-infection. Furthermore, Simcere is also expanding its presence in disease areas with high clinical needs in the future.

Simcere's industry-leading capabilities and commitment to synergistic innovation have also enabled numerous strategic collaborations and are viewed as the partner of choice by innovative biopharmaceutical companies, medical institutes and research teams in China And on a global level.

For more information, please visit: www.simcere.com

About FZ002-037

FZ002-037 is an off-the-shelf, phase II non-opioid pain treatment that acts as an oral SSTR4 agonist. It is the first SSTR4 agonist to enter clinical trials China The second is globally. The drug shows excellent selectivity, with a double pM EC50 and strong efficacy in several models of chronic and acute pain. Phase I studies revealed a favorable safety profile, with no CNS or GI adverse events, and an attractive PK profile (possible once-daily dosing). These properties highlight its potential as a cutting-edge therapeutic option to address the unmet need for effective, non-addictive pain relief.

For more information, please visit: https://www.fulmz.com

Contact for investors and media: pr@fulmz.com